PTC Therapeutics, Inc. (PTCT) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 5.22B USD. 52-week range 61.23 to 90.87 USD. Trailing P/E 8.6. Data as of 2026-10-09.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat ...